The Progressive Supranuclear Palsy Clinical Trial Platform

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

440

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2029

Conditions
Progressive Supranuclear Palsy(PSP)
Interventions
BIOLOGICAL

AADvac1

Active immunotherapy

DRUG

Treatment B

Tau-directed, neuroprotective or other therapy

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Alzheimer's Therapeutic Research Institute

OTHER

collaborator

University of Southern California

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

University of California, San Diego

OTHER

collaborator

Alzheimer's Clinical Trials Consortium

OTHER

lead

Adam Boxer

OTHER

NCT07173803 - The Progressive Supranuclear Palsy Clinical Trial Platform | Biotech Hunter | Biotech Hunter